Robert J. Motzer, MD

Robert J. Motzer, MD, attending physician, Memorial Sloan Kettering Cancer Center, discusses nivolumab for the treatment of metastatic renal cell carcinoma.

Nivolumabâ€™s novel mechanism of action makes it potentially useful for RCC.

Nivolumab looks promising in this space because of its durability of responses, impact on survival, and favorable safety profile.

Nivolumab is being compared with everolimus in patients with clear cell mRCC. OS is the primary endpoint.

Robert J. Motzer, MD | Authors

Articles

Nivolumab for the Treatment of mRCC